Status:

NOT_YET_RECRUITING

Evaluation of the Non-inferiority of Resorbable Gelatin Embolization Compared to Embolization Combined With Endometrial Aspiration for the Management of Hemorrhagic Uterine Vascular Abnormalities Following Premature Termination of Pregnancy

Lead Sponsor:

University Hospital, Grenoble

Collaborating Sponsors:

University Hospital, Bordeaux

University Hospital, Clermont-Ferrand

Conditions:

Hemorrhage, Obstetric

Uterine Abnormality

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

The goal of this clinical trial is to determine the best treatment for patients who experience vaginal bleeding following a premature termination of pregnancy. The main questions it aims to answer ar...

Detailed Description

Ten to 15% of pregnancies end in the first trimester. Voluntary termination of pregnancy and spontaneous miscarriage, the two main causes of pregnancy loss, are managed medically or surgically in orde...

Eligibility Criteria

Inclusion

  • Patient who experienced a miscarriage within 3 months
  • Patient with gynecological bleeding
  • Patient presenting with hypervascularized uterine retention with negative Doppler ultrasound findings (endometrial hypervascularization with 1) systolic peak velocity greater than 70 cm/s and/or 2) resistance index (RI) within the retention \< 0.5)
  • Patient affiliated to french social security
  • Patient who has signed the written informed consent form

Exclusion

  • Patient presenting to the emergency department with hemorrhagic shock: systolic blood pressure \< 90 mmHg associated with tachycardia \> 120 bpm
  • Severe renal failure (glomerular filtration rate \< 30 mL/min)
  • Medical history of severe allergy to iodinated contrast media
  • Severe coagulation disorders (platelets \<50G/L, PT \< 50%)
  • Anticoagulant and/or antiplatelet agent that cannot be discontinued a few days before the procedure
  • Patient referred to in Articles L1121-5, L1121-6, and L1121-8 of the French Public Health Code
  • Staff with a hierarchical relationship to the principal investigator
  • Patient in the exclusion period of another study
  • Patient cannot be contacted in an emergency
  • Participation in other interventional studies during the study period

Key Trial Info

Start Date :

January 1 2026

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2028

Estimated Enrollment :

110 Patients enrolled

Trial Details

Trial ID

NCT07206342

Start Date

January 1 2026

End Date

December 31 2028

Last Update

October 3 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

CHU de Bordeaux

Bordeaux, France, 33000

2

CHU de Clermont-Ferrand-Gabriel Montpied

Clermont-Ferrand, France, 63000

3

CHU Grenoble Alpes

Grenoble, France, 38000

4

CHU de St Etienne-Hôpital Nord

Saint-Etienne, France, 42000